Mylan obtained the patent and manufacturing rights for the EpiPen injector in 2007. Over the past ten years, Mylan has had to increase the price of the injector, from $100 at the time of obtaining the EpiPen to $608 in 2017, to meet the expense demands of their supply chain. This drastic price increase in this life-saving device has brought scrutiny to the firm as another greedy pharmaceutical giant (Popken, 2016). This increase has caused the firm to fall under investigation by the Federal Trade Commission (FTC), which was brought on by New York Attorney General Eric Schneiderman, Senators Richard Blumenthal and Amy Klobuchar (McLaughlin, Forden, and Hopkins, 2017).
Being under the magnifying glass of the public eye has come at a time when Mylan had come to a settlement with the Department of Justice (DOJ) for allegations of misrepresenting the EpiPen as a generic …show more content…
These actions include (1) extending the current EpiPen rebate program for patients to bring the product back to 2007 prices; (2) introducing a true generic alternative to the EpiPen; (3) co-manufacturing with other current generic alternatives, Teva and Sanofi, to alleviate the market strain; (4) ease restrictions for EpiPen4Schools participants and allow them to purchase current market alternatives; (5) holding a press conference explaining the increased price of the product and pointing fault with insurance company premiums increase through the Affordable Care Act (ACA); (6) have current CEO Heather Bresch resign and replaced; (7) evaluate current supply chain and possibly open new distributor networks to lower current costs; (8) redevelop the current EpiPen container to extend the life of the medicine and lower cost for patients; (9) create a faux-competitor that will compete in the same market and hopefully draw away the current “heat” from the
Being under the magnifying glass of the public eye has come at a time when Mylan had come to a settlement with the Department of Justice (DOJ) for allegations of misrepresenting the EpiPen as a generic …show more content…
These actions include (1) extending the current EpiPen rebate program for patients to bring the product back to 2007 prices; (2) introducing a true generic alternative to the EpiPen; (3) co-manufacturing with other current generic alternatives, Teva and Sanofi, to alleviate the market strain; (4) ease restrictions for EpiPen4Schools participants and allow them to purchase current market alternatives; (5) holding a press conference explaining the increased price of the product and pointing fault with insurance company premiums increase through the Affordable Care Act (ACA); (6) have current CEO Heather Bresch resign and replaced; (7) evaluate current supply chain and possibly open new distributor networks to lower current costs; (8) redevelop the current EpiPen container to extend the life of the medicine and lower cost for patients; (9) create a faux-competitor that will compete in the same market and hopefully draw away the current “heat” from the